Overall response rate stratified by novel SA vs CA in patients with R/R PTCL in phase I, II, and III clinical trials subdivided by histological subtype
| . | Novel SA . | Combination chemotherapy . | P value . |
|---|---|---|---|
| PTCL-NOS | 0.31 [0.27, 0.35] (n = 49)* | 0.42 [0.28, 0.58] (n = 6) | .16 |
| AITL | 0.43 [0.36, 0.50] (n = 30) | 0.22 [0.03, 0.70] (n = 2) | .37 |
| ALCL | 0.48 [0.36, 0.60] (n = 20) | 0.34 [0.17, 0.57] (n = 2) | .31 |
| NK/TCL | 0.52 [0.42, 0.61] (n=9) | 0.63 [0.34, 0.86] (n=1) | .46 |
| . | Novel SA . | Combination chemotherapy . | P value . |
|---|---|---|---|
| PTCL-NOS | 0.31 [0.27, 0.35] (n = 49)* | 0.42 [0.28, 0.58] (n = 6) | .16 |
| AITL | 0.43 [0.36, 0.50] (n = 30) | 0.22 [0.03, 0.70] (n = 2) | .37 |
| ALCL | 0.48 [0.36, 0.60] (n = 20) | 0.34 [0.17, 0.57] (n = 2) | .31 |
| NK/TCL | 0.52 [0.42, 0.61] (n=9) | 0.63 [0.34, 0.86] (n=1) | .46 |
Numbers in parenthesis represent number of clinical trials included for analysis in that category.